Antimuscarinic action of oxymetazoline on human intraocular muscles

Journal of Ocular Pharmacology and Therapeutics

Volumn 20, Issue 4, 2004, Pages 328-332

  Patil, Popat N ^a   Ishikawa, Hitoshi ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ATROPINE; CARBACHOL; DECONGESTIVE AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYMETAZOLINE;

ANTICHOLINERGIC EFFECT; ARTICLE; CILIARY MUSCLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOSE RESPONSE; HUMAN; HUMAN TISSUE; MUSCLE TONE; SPHINCTER PUPILLAE MUSCLE; VASOCONSTRICTION;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MUSCARINIC ANTAGONISTS; OCULOMOTOR MUSCLES; OXYMETAZOLINE;

EID: 4243193693     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/1080768041725335     Document Type: Article

References (15)

1. Mujic, M., and Van Rossum, J.M. Comparative pharmacodynamics of sympathomimetic imidazolines. Studies on intestinal smooth muscle of the rabbit and the cardiovascular system of the cat. Arch. Int. Pharmacodyn. 155:432-449, 1965.
2. Sanders, J., Miller, D.D., and Patil, P.N. Alpha adrenergic and histaminergic effects of tolazoline-like imidazolines. J. Pharmacol. Exptl. Ther. 195:362-371, 1975.
3. Ishikawa, H., Miller, D.D., and Patil, P.N. Comparison of postjunctional α-adrenoceptors in iris dilator muscle of humans and albino and pigmented rabbits N.S. Arch. Pharmacol. 354:765-772, 1996.
4. Reis, D., Bousquet, P., and Parini, A. (eds). The imidazolines receptor: Pharmacology, functions, ligands, and relevance to biology and medicine. Ann. N.Y. Acad. Scis. 763:1-707, 1995.
5. Patil, P.N. Reactivity of human sphincter to muscarinic drugs in vitro. N.S. Arch. Pharmacol. 346:614-619, 1992.
6. Van Rossum, J.M., and Van Den-Brink, F.G. Cumulative dose-response curves I: Introduction to the technique. Arch. Int. Pharmacodyn. Ther. 143:240-246, 1963.
7. Arunlakshana, O., and Schild, H.O. Some quantitative uses of drug antagonists. Brit. J. Pharmacol. 14:48-58, 1959.
8. Furchgott, R.F. The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In: Blaschko, H., and Muscholl, E. (eds.). Catecholamine. New York: Springer-Verlag, 1972:283-335.
9. Schild, H.O. pA, a new scale for the measurement of drug antagonism. Brit. J. Pharmacol. 2:189-206, 1947.
10. Gaddum, J.H. The quantitative effects of antagonistic drugs. J. Physiol. 87:7P-9P, 1937.
11. Friedman, H.L. Influence of isosteric replacement upon biological activity. National Academy of Sciences, National Research Council Publication No. 206. Washington, DC: U.S. Government Printing Office, 1951:251.
12. Bovet, D. The relations between isosterism and competitive phenomenon in the field of drug therapy of the autonomic nervous system and that of the neuromuscular transmission. Nobel Lectures, Physiology, and Medicine. New York: Elsevier, 1964:552.
13. Patil, P.N. Enhanced sensitivity of the iris sphincter to the muscarinic agonist carbachol at lower temperature. J. Ocular. Pharmacol. Ther. 15:65-72, 1999.
14. Patil, P.N. Reversal of cholinergic response of intraocular muscles by atropine: drug antagonism reexamined. In: Gupta, S.K. (ed.). Pharmacology and Therapeutics in the New Millennium. New Delhi, India: Narosa Publishing House, 2001:579-586.
15. Xuan, B., and Chiou, G.C.Y. Efficacy of oxymetazoline in noninfectious conjunctivitis, the most common cause of acute red eyes. J. Ocular. Pharmacol. Ther. 13:363-367, 1997.